These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19575518)

  • 21. [Whole blood C-reactive protein in internal diseases].
    Mysliaeva AV; Fomicheva SV; Iaglinskaia LV
    Lab Delo; 1982; (1):22-4. PubMed ID: 6174779
    [No Abstract]   [Full Text] [Related]  

  • 22. Early life origins of low-grade inflammation and atherosclerosis risk in children and adolescents.
    Labayen I; Ortega FB; Sjöström M; Ruiz JR
    J Pediatr; 2009 Nov; 155(5):673-7. PubMed ID: 19595364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?
    Ridker PM; Wilson PW; Grundy SM
    Circulation; 2004 Jun; 109(23):2818-25. PubMed ID: 15197153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. C-reactive protein, cardiovascular disease and stroke: new roles for an old biomarker.
    Willcox BJ; Abbott RD; Yano K; Rodriguez BL; Willcox DC; Curb JD
    Expert Rev Neurother; 2004 May; 4(3):507-18. PubMed ID: 15853546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. C-reactive protein and coronary heart disease.
    Foody JM; Gotto AM; Wenger N
    N Engl J Med; 2004 Jul; 351(3):295-8; author reply 295-8. PubMed ID: 15257565
    [No Abstract]   [Full Text] [Related]  

  • 26. [C-reactive protein in cardiovascular diseases].
    Lubas W; Gutkowski K
    Przegl Lek; 2006; 63(7):562-6. PubMed ID: 17203810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years.
    Kvetny J; Heldgaard PE; Bladbjerg EM; Gram J
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):232-8. PubMed ID: 15272919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of a high-sensitivity C-reactive protein assay in evaluating cardiovascular disease risk.
    Luhr TA
    Am Clin Lab; 2000; 19(9):20-1. PubMed ID: 11193978
    [No Abstract]   [Full Text] [Related]  

  • 29. [CRP--a marker of a pro-inflammatory state and cardiovascular risk].
    Poledne R; Valenta Z; Pit'ha J
    Vnitr Lek; 2007 Apr; 53(4):391-5. PubMed ID: 17578172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measurement of C-reactive protein and natriuretic peptides for cardiovascular risk assessment: the need for age and gender-specific thresholds.
    Dotsenko O; Chackathayil J; Lip GY
    J Hypertens; 2008 Jan; 26(1):11-3. PubMed ID: 18090533
    [No Abstract]   [Full Text] [Related]  

  • 31. C-reactive protein: "cutoff" point and clinical applicability.
    Tsirpanlis G; Alevyzaki F; Triantafyllis G; Chatzipanagiotou S; Nicolaou C
    Am J Kidney Dis; 2005 Aug; 46(2):368; author reply 369. PubMed ID: 16112061
    [No Abstract]   [Full Text] [Related]  

  • 32. High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors.
    Olsen MH; Christensen MK; Hansen TW; Gustafsson F; Rasmussen S; Wachtell K; Borch-Johnsen K; Ibsen H; Jørgensen T; Hildebrandt P
    J Hypertens; 2006 Apr; 24(4):655-61. PubMed ID: 16531793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High sensitivity C-reactive protein for predicting cardiovascular disease: an inflammatory hypothesis.
    Blake GJ; Ridker PM
    Eur Heart J; 2001 Mar; 22(5):349-52. PubMed ID: 11207073
    [No Abstract]   [Full Text] [Related]  

  • 34. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein.
    Koenig W
    Int J Cardiol; 2005 Feb; 98(2):199-206. PubMed ID: 15686768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leukocyte count in vascular risk prediction.
    Cushman M
    Arch Intern Med; 2005 Mar; 165(5):487-8. PubMed ID: 15767523
    [No Abstract]   [Full Text] [Related]  

  • 36. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the laboratory science discussion group.
    Myers GL; Rifai N; Tracy RP; Roberts WL; Alexander RW; Biasucci LM; Catravas JD; Cole TG; Cooper GR; Khan BV; Kimberly MM; Stein EA; Taubert KA; Warnick GR; Waymack PP; ;
    Circulation; 2004 Dec; 110(25):e545-9. PubMed ID: 15611379
    [No Abstract]   [Full Text] [Related]  

  • 37. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
    Sellmayer A; Limmert T; Hoffmann U
    Int Angiol; 2003 Mar; 22(1):15-23. PubMed ID: 12771851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment.
    Libby P; Ridker PM
    Am J Med; 2004 Mar; 116 Suppl 6A():9S-16S. PubMed ID: 15050187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of fear of terror with low-grade inflammation among apparently healthy employed adults.
    Melamed S; Shirom A; Toker S; Berliner S; Shapira I
    Psychosom Med; 2004; 66(4):484-91. PubMed ID: 15272092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events.
    Mora S; Rifai N; Buring JE; Ridker PM
    Circulation; 2006 Aug; 114(5):381-7. PubMed ID: 16864722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.